JnJ to acquire Intra-Cellular Therapies for USD 14.6 billion Ruchika Sharma15 Jan 2025 11:30 AM ISTNew Brunswick: Johnson & Johnson and Intra-Cellular Therapies, Inc. have announced that they have entered into a definitive agreement under...
Promotion of Sugary Drinks? ORSL Stall at Pedicon Conference Leads to Controversy Barsha Misra14 Jan 2025 5:34 PM ISTHyderabad: The recently held annual conference of the Indian Academy of Pediatrics (IAP) led to a controversy after the event included an...
JnJ Nipocalimab gets USFDA Priority Review designation for generalized myasthenia gravis Ruchika Sharma12 Jan 2025 3:30 PM ISTSpring House: Johnson & Johnson has announced the nipocalimab Biologics License Application (BLA) has received Priority Review designation...
JnJ temporarily pauses rollout of Varipulse heart device in US Ruchika Sharma11 Jan 2025 5:35 PM ISTJohnson & Johnson has announced a temporarily pause in the rollout of its Varipulse heart device in the United States as it investigates four...
JnJ Posdinemab gets USFDA Fast Track Designation for treatment of Alzheimer's disease Ruchika Sharma9 Jan 2025 1:30 PM ISTPosdinemab is an investigational monoclonal antibody that targets the mid-domain of Alzheimer's disease-specific phosphorylated tau.
JnJ enters licensing agreement for global development, manufacturing, commercialization of STAT6 program from Kaken Pharma Ruchika Sharma27 Dec 2024 10:00 AM ISTNew Brunswick: Johnson & Johnson has announced that it has entered into an exclusive licensing agreement for the global...
JnJ seeks USFDA approval for Simponi to treat pediatric ulcerative colitis Ruchika Sharma19 Dec 2024 12:42 PM ISTDeveloped by Johnson & Johnson, SIMPONI is an anti-TNF biologic medicine that targets and blocks a protein called TNF-alpha.
JnJ seeks USFDA nod for Tremfya for treatment of plaque psoriasis, juvenile psoriatic arthritis in children Ruchika Sharma3 Dec 2024 12:30 PM ISTSpring House: Johnson & Johnson has announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and...
JnJ seeks USFDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis Ruchika Sharma29 Nov 2024 11:30 AM ISTSpring House: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
JnJ MedTech gets IDE approval for OTTAVA Robotic Surgical System Ruchika Sharma15 Nov 2024 5:05 PM ISTNew Brunswick: Johnson & Johnson MedTech has announced that the U.S. Food & Drug Administration (USFDA) has approved the OTTAVA...
USFDA grants Breakthrough Therapy Designation to Nipocalimab for treatment of adults with moderate-to-severe Sjögren's disease: JnJ Ruchika Sharma12 Nov 2024 1:00 PM ISTSpring House: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy...
JnJ seeks approval from USFDA, EMA for DARZALEX FASPRO as subcutaneous monotherapy for high-risk smoldering multiple myeloma Ruchika Sharma10 Nov 2024 4:15 PM ISTRaritan: Johnson & Johnson has announced the submission of regulatory applications to the U.S. Food and Drug Administration (FDA) and...
